Researchers at Carnegie Mellon University have developed a groundbreaking lens technology that enables a camera to focus on ...

As of Monday, December 29, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.24%, which has investors questioning ...

The depth-defying lens can focus on multiple objects at different distances.

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

A new microchip-sized device could dramatically accelerate the future of quantum computing. It controls laser frequencies ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or ...

Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified ...